|
INN name:
|
Gilteritinib
|
|||||||||
|
Lab codes:
|
ASP-2215
|
|||||||||
|
|
|
|||||||||
|
Chemical name:
|
6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide
|
|||||||||
|
Molecular formula:
|
C29H44N8O3
|
|||||||||
|
Chemical Structure:
|
 |
|||||||||
|
CAS Registry Number:
|
1254053-43-4
|
|||||||||
|
Originator:
|
Astellas Pharma
|
|||||||||
|
Class:
|
Antineoplastic
|
|||||||||
|
Mechanism of Action:
|
Tyrosine kinase
inhibitor
|
|||||||||
|
WHO ATC code:
|
L01X-E
|
|||||||||
|
EPhMRA code:
|
L1H
|
|||||||||
|
Clinical Trials:
|
||||||||||
|
|
||||||||||
|
|
||||||||||
|
Recent activities on the
drug:
|
||||||||||
Monday 14 September 2015
Gilteritinib
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment